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Abstract
Loss of either hepatocyte growth factor activator inhibitor (HAI)-1 or -2 is associated with embryonic lethality in mice, which
can be rescued by the simultaneous inactivation of the membrane-anchored serine protease, matriptase, thereby
demonstrating that a matriptase-dependent proteolytic pathway is a critical developmental target for both protease
inhibitors. Here, we performed a genetic epistasis analysis to identify additional components of this pathway by generating
mice with combined deficiency in either HAI-1 or HAI-2, along with genes encoding developmentally co-expressed
candidate matriptase targets, and screening for the rescue of embryonic development. Hypomorphic mutations in Prss8,
encoding the GPI-anchored serine protease, prostasin (CAP1, PRSS8), restored placentation and normal development of
HAI-1–deficient embryos and prevented early embryonic lethality, mid-gestation lethality due to placental labyrinth failure,
and neural tube defects in HAI-2–deficient embryos. Inactivation of genes encoding c-Met, protease-activated receptor-2
(PAR-2), or the epithelial sodium channel (ENaC) alpha subunit all failed to rescue embryonic lethality, suggesting that
deregulated matriptase-prostasin activity causes developmental failure independent of aberrant c-Met and PAR-2 signaling
or impaired epithelial sodium transport. Furthermore, phenotypic analysis of PAR-1 and matriptase double-deficient
embryos suggests that the protease may not be critical for focal proteolytic activation of PAR-2 during neural tube closure.
Paradoxically, although matriptase auto-activates and is a well-established upstream epidermal activator of prostasin,
biochemical analysis of matriptase- and prostasin-deficient placental tissues revealed a requirement of prostasin for
conversion of the matriptase zymogen to active matriptase, whereas prostasin zymogen activation was matriptase-
independent.
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Introduction
Studies conducted within the past two decades have uncovered
a large family of membrane-anchored serine proteases that
regulates vertebrate development, tissue homeostasis, and tissue
repair by providing focal proteolysis essential for cytokine and
growth factor maturation, extracellular matrix remodeling,
signaling receptor activation, receptor shedding, regulation of
ion channel activity, and more (reviewed in [1,2,3]). Individual
members of this family regulate both vertebrate development and
postnatal tissue homeostasis, including auditory and vestibular
system development [4,5,6], differentiation of stratified epithelia
[7,8], loss of epithelial tight junction function [9,10], failure to
activate digestive enzymes [11], thyroid hormone availability [4],
sodium and water homeostasis [12,13,14], iron homeostasis
[15,16], and fertility [17,18]. Likewise, mounting evidence suggests
that excessive or spatially dysregulated membrane-anchored serine
protease activity contributes to several human disorders, including
congenital malformations [19], epithelial dysfunction [20,21,22],
and cancer [3].
Matriptase is a modular type II transmembrane serine protease,
encoded by the ST14 gene, that has pleiotropic functions in
epithelial development and postnatal homeostasis, at least in part
through its capacity to regulate epithelial tight junction formation
in simple and stratified epithelia [2,3]. In the human and mouse
epidermis, matriptase appears to function as part of a proteolytic
cascade in which it acts upstream of the GPI-anchored serine
protease prostasin (CAP1/PRSS8), most likely by directly activat-
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ing the prostasin zymogen [23,24,25,26]. Several additional
candidate proteolytic substrates have been identified for matrip-
tase in cell-based and biochemical assays, including growth factor
precursors [27,28,29,30], protease-activated signaling receptors
[31,32,33], ion channels [34,35], and other protease zymogens
besides pro-prostasin [29,36,37]. However, the extent to which
cleavage of these substrates is critical to matriptase-dependent
epithelial development and maintenance of epithelial homeostasis
needs to be established.
Although matriptase is not required for term development in
humans and most mouse strains ([24,38], and Szabo et al.,
unpublished data), the membrane-anchored serine protease
nevertheless is expressed in many burgeoning embryonic as well
as extraembryonic epithelia [39,40,41,42]. Furthermore, we have
previously shown that matriptase must be tightly regulated at the
post-translational level, for successful execution of several devel-
opmental processes. Thus, loss of either of the two Kunitz-type
transmembrane serine protease inhibitors, hepatocyte growth
factor activator inhibitor (HAI)-1 or -2 or combined haploinsuffi-
ciency for both inhibitors, is associated with uniform embryonic
lethality in mice [40,43]. Loss of HAI-1 or combined haploinsuf-
ficiency for HAI-1 and HAI-2 causes mid-gestation embryonic
lethality due to failure to develop the placental labyrinth. Loss of
HAI-2, in turn, is associated with three distinct phenotypes: a)
Early embryonic lethality, b) mid-gestation lethality due to
placental labyrinth failure, and c) neural tube defects resulting in
exencephaly, spina bifida, and curly tail. All developmental defects
in HAI-1- and HAI-2-deficient embryos, however, are rescued in
whole or in part by simultaneous matriptase-deficiency, thus
demonstrating that a matriptase-dependent proteolytic pathway is
a critical morphogenic target for both protease inhibitors ([43,44],
this study).
In this study, we exploited the observation that HAI-1- and
HAI-2-deficient mice display matriptase-dependent embryonic
lethality with complete penetrance to perform a comprehensive
genetic epistasis analysis aimed at identifying additional compo-
nents of the matriptase proteolytic pathway. Specifically, we
generated mice with simultaneous ablation of either the Spint1
gene (encoding HAI-1) or the Spint2 gene (encoding HAI-2) along
with genes encoding candidate matriptase targets that are co-
expressed with the protease during development. We then
screened for the rescue of embryonic lethality or restoration of
HAI-1 and HAI-2-dependent morphogenic processes in these
double-deficient mice. This analysis identified prostasin as critical
to all matriptase-induced embryonic defects in both HAI-1- and
HAI-2-deficient mice. Paradoxically, however, although matrip-
tase autoactivates efficiently and prostasin is incapable of
undergoing autoactivation, we found that prostasin acts upstream
of matriptase in the developing embryo and is required for
conversion of the matriptase zymogen to active matriptase.
Finally, we explored the contribution of this newly identified
prostasin-matriptase pathway to protease-activated receptor
(PAR)-dependent signaling during neural tube formation [45]
and now provide evidence that the pathway may be separate from
the proteolytic machinery that mediates focal activation of PAR-2
during neural tube closure.
Results
Developmental defects in HAI-2–deficient mice tightly
correlate with matriptase expression levels
HAI-2-deficient (Spint22/2) mice were originally reported to
display embryonic lethality prior to embryonic day 8 (E8.0),
presenting with severe clefting of the embryonic ectoderm at E7.5
and a failure to progress to the headfold stage [44]. We previously
reported, however, that approximately 50% of HAI-2-deficient
mice complete early development but die at midgestation due to
defective placental branching morphogenesis [43]. However, the
genotyping strategy used in the latter study aimed at exploring the
contribution of matriptase to this embryonic demise and only
allowed for the discrimination of HAI-2-deficient mice on
matriptase-sufficient (wildtype, Spint22/2;St14+/+, or haploinsuffi-
cient, Spint22/2;St14+/2) backgrounds from a matriptase-deficient
(Spint22/2;St142/2) background. Therefore, to test the possibility
that early embryonic development of HAI-2-deficient mice is St14
gene dosage-dependent, we first analyzed the offspring of
interbred Spint2+/2;St14+/2 mice at various developmental stages.
This analysis revealed that the various developmental phenotypes
seen in HAI-2-deficient mice, indeed, were strongly dependent on
St14 gene dosage (Figure 1A). Thus, HAI-2-deficient embryos
carrying two wildtype matriptase alleles (St14+/+), displayed early
lethality, as evidenced by only five percent of Spint22/2;St14+/+
embryos developing beyond E9.0 and none past E10.5 (Figure 1A,
blue diamonds). Inactivation of one matriptase allele (Spint22/2;
St14+/2), however, was sufficient to partially rescue this early
embryonic lethality of HAI-2-deficient mice (Figure 1A, red
squares). As reported previously [43], inactivation of both alleles of
matriptase (Spint22/2;St142/2) completely restored embryonic
survival and placental development and also reduced the
occurrence of neural tube defects associated with the loss of
HAI-2 (Figure 1A, green triangles and Table 1). Taken together,
these findings show that loss of HAI-2 may lead to three distinct
developmental phenotypes, dependent on the overall expression
level of matriptase (Table 1): (i) early embryonic lethality occurring
largely prior to E8.5, which can be partially rescued by matriptase
haploinsufficiency (Spint22/2;St14+/2) and completely by matrip-
tase deficiency (Spint22/2;St142/2); (ii) placental defects resulting in
mid-gestation lethality, which are observed in Spint22/2;St14+/2
embryos after E9.5, but are absent in Spint22/2;St142/2 embryos,
Author Summary
Vertebrate embryogenesis is dependent upon a series of
precisely coordinated cell proliferation, migration, and
differentiation events. Recently, the execution of these
events was shown to be guided in part by extracellular
cues provided by focal pericellular proteolysis by a newly
identified family of membrane-anchored serine proteases.
We now show that two of these membrane-anchored
serine proteases, prostasin and matriptase, constitute a
single proteolytic signaling cascade that is active at
multiple stages of development. Furthermore, we show
that failure to precisely regulate the enzymatic activity of
both prostasin and matriptase by two developmentally co-
expressed transmembrane serine protease inhibitors,
hepatocyte growth factor activator inhibitor-1 and -2,
causes an array of developmental defects, including clefting
of the embryonic ectoderm, lack of placental labyrinth
formation, and inability to close the neural tube. Our study
also provides evidence that the failure to regulate the
prostasin–matriptase cascade may derail morphogenesis
independent of the activation of known protease-regulated
developmental signaling pathways. Because hepatocyte
growth factor activator inhibitor–deficiency in humans is
known to cause an assortment of common and rare
developmental abnormalities, the aberrant activity of the
prostasin–matriptase cascade identified in our study may
contribute importantly to genetic as well as sporadic birth
defects in humans.
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Figure 1. Effect of St14 gene dosage and c-Met activity on embryonic development in HAI-1– and HAI-2–deficient mice. (A) Matriptase
haploinsufficiency partially restores early embryonic development of HAI-2 deficient mice. Relative frequency of Spint22/2;St14+/+ (blue diamonds
and trend line), Spint22/2;St14+/2 (red squares and trendline), and Spint22/2;St142/2 (green triangles and trendline) embryos in offspring from
interbred Spint2+/2;St14+/2 mice at E8.5–E15.5. The expected 25% Mendelian frequency is shown with the dotted trend line. 59–250 embryos were
genotyped at each stage. (B) Matriptase haploinsufficiency does not rescue development of HAI-1-deficient mice. Genotype distribution of E8.5–E11.5
embryos and newborn (P1) offspring from interbred Spint1+/2;St14+/2 mice. No living St14+/+;Spint12/2 or St14+/2;Spint12/2 embryos are observed
after E9.5. (C) Distribution of Spint1 genotypes in c-Met-expressing (Hgfr+/+ or Hgfr+/2, blue bars) and c-Met-deficient (Hgfr2/2, green bars) embryos
from interbred Spint1+/2;Hgfr+/2 mice at E11.5–13.5. Loss of c-Met activity does not improve embryonic survival of HAI-1-deficient mice. (D and E)
Distribution of Spint2 genotypes in c-Met-expressing (Hgfr+/+ or Hgfr+/2, blue bars) and c-Met-deficient (Hgfr2/2, green bars) embryos from
Spint2+/2;Hgfr+/26Spint2+/2;Hgfr+/2 (D) or Spint2+/2;Hgfr+/26Spint2+/2;Hgfr+/2;St14+/2 (E) breeding pairs at E9.5–10.5. Only St14+/2 embryos are
shown in (E). Loss of c-Met does not improve survival of HAI-2-deficient embryos. (F) Frequency of exencephaly observed in 153 control
(Spint2+;Hgfr+), 53 c-Met- (Spint2+;Hgfr2/2), 24 HAI-2- (Spint22/2,Hgfr+), and 6 c-Met and HAI-2 double- (Spint22/2;Hgfr2/2) deficient embryos at E9.5.
Loss of c-Met activity fails to correct neural tube defects in HAI-2-deficient mice.
doi:10.1371/journal.pgen.1002937.g001
Table 1. Developmental defects observed in Spint1- and Spint-2-deficient mice as function of St14 expression.
Genotype Phenotype Penetrance
St14+/+ St14+/2 St142/2
Spint12/2 Lack of placental labyrinth, embryonic lethality
at E10.5
100% 100% (no rescue) 0% (complete rescue)
Spint22/2 Early embryonic lethality at E9.5 or earlier 100% 45% (partial rescue) 0% (complete rescue)
Incomplete differentiation of placental
labyrinth, embryonic lethality at E10.5–E14.5
N/A 100% (no rescue) 0% (complete rescue)
Neural tube defects N/A
Exencephaly 95–100% 18% (partial rescue; P,0.0001)
Spina bifida 11% 13% (no rescue)
Curly tail 89% 62% (partial rescue?; not
significant)
doi:10.1371/journal.pgen.1002937.t001
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and (iii) neural tube defects observed at or after E8.5 in most
Spint22/2;St14+/2 embryos, and partially rescued in Spint22/2;
St142/2 embryos and term offspring.
We next performed a similar analysis of the effect of St14 gene
dosage on the developmental defects and embryonic lethality
associated with HAI-1-deficiency by analyzing the offspring from
interbred Spint1+/2/St14+/2 mice (Figure 1B). As shown previ-
ously [40], a complete rescue of both the placental defects and
embryonic lethality was observed in HAI-1-deficient mice
expressing no matriptase (Spint12/2;St142/2). However, compar-
ison of HAI-1-deficient mice carrying one (Spint12/2;St14+/2) or
two (Spint12/2;St14+/+) wildtype St14 alleles revealed identical
defects in placental labyrinth formation and mid-gestation
embryonic lethality occurring with complete penetrance
(Figure 1B, Table 1, and data not shown).
Activation of hepatocyte growth factor (HGF) does not
contribute to placental defects in HAI-1–deficient
embryos or early embryonic lethality and neural tube
defects in HAI-2–deficient mice
Matriptase is an efficient activator of proHGF [29,30] and
dysregulated matriptase activity recently was shown to promote
squamous cell carcinoma through activation of HGF-dependent c-
Met signaling [46]. Furthermore, both proHGF and its cognate
receptor c-Met are expressed during embryogenesis in both the
placenta and the embryo [47,48]. To investigate the involvement
of aberrant proHGF activation and c-Met signaling in the etiology
of the defects observed in HAI-1- and HAI-2-deficient embryos,
we took advantage of the fact that c-Met is only required for
embryonic development beyond E13.5 [47,48]. This enabled the
study of key HAI-1- and HAI-2-dependent morphogenic processes
in mice homozygous for a null mutation in Hgfr (Hgfr2/2),
encoding c-Met. Analysis of embryos from interbred Spint1+/2;
Hgfr+/2 mice at E11.5–E13.5 revealed only one surviving
Spint12/2;Hgfr2/2 embryo, indicating that the loss of c-Met
activity does not restore placental development or embryonic
survival of HAI-1-deficient mice (Figure 1C, P,0.04, Chi-square
test, and data not shown). Likewise, no Spint22/2;Hgfr2/2
embryos were detected beyond E9.5 (Figure 1D, P,0.02, Chi-
square test), indicating that the inactivation of c-Met signaling does
not prevent matriptase-induced early embryonic lethality in HAI-
2-deficient mice. Interbreeding Spint2+/2;Hgfr+/2;St14+/2 mice
allowed for the analysis of the impact of c-Met deficiency on the
formation of neural tube defects in HAI-2-deficient mice by
preventing early embryonic lethality (Figure 1E). However, all of
the Spint22/2;Hgfr2/2;St14+/2 embryos isolated at E9.5 from
these crosses presented with exencephaly (Figure 1F), suggesting
that c-Met signaling is not critically involved in the neural tube
defects caused by the absence of HAI-2. All Spint22/2;
Hgfr2/2;St14+/2 embryos displayed synthetic lethality after E9.5,
which precluded the direct analysis of the impact of c-Met loss on
the defects in placental differentiation caused by HAI-2 deficiency
(data not shown). Taken together, these findings suggest that
aberrant HGF-c-Met signaling does not contribute to the
matriptase-dependent defects in placentation in HAI-1-deficient
embryos, or early lethality and neural tube closure of HAI-2-
deficient embryos.
Reduced prostasin enzymatic activity prevents
developmental defects in both HAI-1– and HAI-2–
deficient mice
The GPI-anchored membrane serine protease, prostasin
(CAP1/PRSS8), is a well-validated downstream proteolytic target
for matriptase in the epidermis of mice and humans (see
Introduction). To explore the possibility that matriptase acts
through prostasin to cause the signature defects in embryonic
development of HAI-1- and HAI-2-deficient mice, we first
performed a detailed immunohistochemical analysis of prostasin
expression in the developing embryo by staining histological
sections from wildtype (Prss8+/+) and littermate prostasin-deficient
(Prss82/2) embryos with prostasin antibodies. Interestingly,
prostasin was expressed in both the surface ectoderm, specifically
covering the converging neuroepithelium at the time of the neural
tube closure (Figure 2A and 2B, compare with 2C), and in the
developing placenta, where expression was detected as early as on
E8.5 and was present in the placental labyrinth in the entire period
of placental differentiation (Figure 2D, 2E, 2G, and 2H, compare
with 2F and 2I), thereby displaying co-expression with matriptase,
HAI-1 and HAI-2 [40,41,42,43,45]. We, therefore, next directly
determined the contribution of prostasin to the matriptase-
dependent developmental defects of HAI-1- and HAI-2-deficient
mice. For this purpose, we exploited the fact that the spontaneous
mutant mouse strain, frizzy, recently was described to be
homozygous for a point mutation in the coding region of the
Prss8 gene (Prss8fr/fr). This mutation results in a non-conservative
V170D amino acid substitution in the prostasin protein [49].
Moreover, this mutant mouse strain completes development, but
displays an epidermal phenotype resembling mice carrying a
hypomorphic mutation in St14 [23], suggesting reduced expression
or enzymatic activity of V170D prostasin. Western blot and
immunohistochemical analysis of tissues from Prss8fr/fr mice did
not reveal an obvious reduction in the level of V170D prostasin
expression when compared to wildtype prostasin in Prss8+/+
littermates (data not shown). Therefore, to assess the enzymatic
activity of the mutant prostasin, we generated enteropeptidase-
activated recombinant V170D prostasin, as well as enteropepti-
dase-activated wildtype and catalytically inactive (S238A) prostasin
variants in HEK293T cells, as described previously [26]. These
recombinant proteins were released from the plasma membrane
by phosphatidylinositol-specific phospholipase C, activated with
enteropeptidase, and their enzymatic activity towards a prostasin-
selective fluorogenic peptide substrate (Figure 2J) as well as their
ability to form enzymatic activity-dependent covalent complexes
with the serpin, protease nexin-1 (PN-1) (Figure 2K), were tested.
As expected, wildtype recombinant prostasin exhibited easily
detectable hydrolytic activity towards the fluorogenic peptide
(Figure 2J, red line) and formed SDS-stable complexes with PN-1
(Figure 2K, compare lanes 3 and 4), while prostasin not activated
by enteropeptidase and the catalytically inactive S238A mutant
and exhibited no detectable hydrolytic activity (Figure 2J, black
and grey lines) or PN-1 binding (Figure 2K and Figure S1A, lanes
2 and 12). V170D prostasin displayed a low residual enzymatic
activity that was above the baseline level, as defined by the
catalytically inactive S238A variant, and corresponded to about
6% of the activity of wildtype prostasin (Figure 2J, blue line), while
complex formation with PN-1 could not be detected (Figure 2K
and Figure S1A, compare lanes 7 and 8). Taken together, these
data indicated that V170D prostasin, expressed by the Prss8fr
allele, displays greatly reduced enzymatic activity. We, therefore,
next interbred Spint1+/2;Prss8fr/+ and Spint1+/2;Prss8fr/fr mice and
analyzed the distribution of Spint1 alleles in the newborn offspring
from these crosses. Consistent with our previous findings, loss of
HAI-1 was not compatible with embryonic survival of mice
carrying a wildtype prostasin allele (Spint12/2;Prss8fr/+) (Figure 3A,
blue bars). Interestingly, however, HAI-1-deficient mice carrying
two mutant prostasin alleles (Spint12/2;Prss8fr/fr) developed to term
(Figure 3A, green bars), although they were found at a frequency
Embryonic Cell Surface Serine Protease Cascade
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Figure 2. Prostasin expression in embryonic and extraembryonic tissues. (A–C) Immunohistochemical detection of prostasin at E8.5 in
epithelial cells of surface ectoderm (examples with arrows in A and B) overlying the cranial neural tube region. Specificity of staining is shown by the
absence of staining of Prss82/2 surface ectoderm (arrow in C). Filled arrowhead shows non-specific staining of yolk sac. No expression was observed
Embryonic Cell Surface Serine Protease Cascade
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that was slightly lower than the expected Mendelian distribution
(20/127, 16% vs. expected 31.75/127, 25%, P,0.05, Chi-square
test). Furthermore, morphometric analysis showed that reduced
prostasin activity fully restored placental labyrinth formation in
HAI-1-deficient embryos, as evidenced by normal histological
appearance of the labyrinth (Figure 3B–3G), thickness of the
labyrinth layer (Figure 3H) and labyrinth vessel density (Figure 3I)
of Spint12/2;Prss8fr/fr embryos. Furthermore, macroscopic and
histological analysis of embryos extracted between E11.5 and
E13.5 failed to reveal any obvious developmental abnormalities
within either embryonic or extraembryonic tissues of
Spint12/2;Prss8fr/fr mice (data not shown), and these mice were
outwardly indistinguishable from their Prss8fr/fr littermates at
weaning and when followed for up to one year (Figure 3J). Taken
together, these data show that the matriptase-mediated develop-
mental defects in HAI-1-deficient mice are prostasin-dependent.
To determine the impact of diminished prostasin activity on the
developmental defects associated with HAI-2-deficiency, we next
analyzed neural tube closure, placental differentiation, and overall
survival of the offspring of interbred Spint2+/2;Prss8fr/+ mice.
Analysis of the genotype distribution of embryos at E9.5–11.5 did
not identify any HAI-2-deficient embryos carrying at least one
wildtype Prss8 allele (Spint22/2;Prss8+/+ or Spint22/2;Prss8fr/+)
(Figure 4A). Interestingly, however, HAI-2-deficient embryos
carrying two mutant Prss8 alleles (Spint22/2;Prss82fr/fr) were found
in the expected Mendelian ratio as late as E13.5–15.5 (Figure 4B,
green bars). Furthermore, genotyping of newborn offspring
revealed the presence of living Spint22/2;Prss8fr/fr pups
(Figure 4C, green bars), although they were found at slightly
lower than expected frequency (15% vs. expected 25%, P,0.06,
Chi-square test). These data strongly suggest that matriptase and
prostasin act as part of a single proteolytic cascade to cause
developmental defects in HAI-2-deficient mice. If this were the
case, we hypothesized that lowering the activity of this cascade
even further by eliminating one St14 allele from Spint22/2;Prss8fr/fr
embryos should additionally improve the term survival of HAI-2-
deficient mice. Indeed, genotyping of born offspring from
interbred Spint2+/2;Prss8fr/+;St14+/2 mice showed a normal
distribution of Spint2 alleles in Prss8fr/fr;St14+/2 pups (Figure 4C,
red bars), further suggesting that failure to regulate a proteolytic
pathway including matriptase and prostasin accounts for all of the
embryonic lethality caused by loss of HAI-2.
As reported previously, neural tube defects, including exence-
phaly, spina bifida, and curly tail were seen in 95–100% of
Spint22/2;Prss8fr/+;St14+/2 mice ([43], this study). Examination of
embryonic and extraembryonic tissues from Spint22/2;Prss8fr/fr
and Spint22/2;Prss8fr/fr;St14+/2 embryos, however, revealed that
reduced prostasin activity sufficed to almost completely rescue the
defects in both neural tube closure and placental differentiation
caused by HAI-2 deficiency. Thus, macroscopic (Figure 4D and
4E) and histological (Figure 4F and 4G) examination of
Spint22/2;Prss8fr/fr;St14+/+ and Spint22/2;Prss8fr/fr;St14+/2 embry-
os showed that, respectively, 5% and 0%, of these embryos
exhibited exencephaly when analyzed after E9.5 (Figure 4H), and
no embryos with either spina bifida or curly tail were observed
(data not shown). Similarly, histological analysis of placental tissues
from E10.5–E13.5 Spint22/2;Prss8fr/fr or Spint22/2;Prss8fr/fr;St14+/
2 embryos did not reveal any of the stereotypic defects associated
with HAI-2 deficiency (Figure 4I and 4J). Thus, the overall
appearance of the placental layers (Figure 4I and 4J), the thickness
of the placental labyrinth (Figure 4K), and the number of fetal
vessels within the labyrinth (Figure 4L), all were comparable to the
HAI-2-sufficient littermate controls. In conclusion, these data
document an essential role of prostasin in the etiology of all of the
developmental defects previously observed in HAI-2-deficient
mice.
Prostasin is required for the activation of matriptase
during development
Matriptase was previously identified as an essential proteolytic
activator of prostasin in the epidermis, and the near ubiquitous co-
localization of the two membrane serine proteases in the epithelial
compartment of most other adult tissues indicate that this
matriptase-prostasin proteolytic pathway may be operating in
multiple epithelia to maintain tissue homeostasis [23,24,25,26].
The genetic epistasis analysis performed above provided strong
evidence that matriptase and prostasin also are part of a single
proteolytic cascade in the context of embryonic development.
Furthermore, the striking overlap in expression of the two
proteases documented earlier in the surface ectoderm during
neural tube closure (see above) was also observed in the developing
placenta (compare Figure 5A and 5B). To further investigate the
functional interrelationship between the two proteases, we
analyzed the levels of the activated forms of matriptase and
prostasin in embryonic and placental tissues from matriptase-
(St142/2) or prostasin- (Prss82/2) deficient mice at E11.5.
Trypsin-like serine proteases are activated by autocatalytic or
heterocatalytic cleavage after an arginine or lysine residue, located
in a conserved activation motif within the catalytic domain.
Activation cleavage severs the bond between the catalytic domain
and upstream accessory domains, but the activated protease
domain remains connected to upstream accessory domains by a
disulfide bond [50]. Zymogen activation, therefore, can be
detected by a mobility shift in reducing SDS-PAGE gels, which
breaks the disulfide bond that keeps the two domains together.
Direct detection of active matriptase in placental tissues by western
blot, however, proved unsuccessful due to low signal intensity and
in the neuroepithelium (A and B, open arrowheads). (D–F) Immunohistochemical detection of prostasin in the chorionic ectoderm (examples with
arrows) of mouse placenta at E8.5. Specificity of staining is shown by the absence of staining of Prss82/2 chorionic ectoderm (F). Filled arrowheads in
D and F shows non-specific staining of trophoblast giant cells. No expression was detected in the trophoblast stem cell-containing chorionic
epithelium (open arrowhead in E). (G–I) Immunohistochemical detection of prostasin in the placental labyrinth (examples with arrows in G and H) of
mouse placenta at E12.5. Specificity of staining is shown by the absence of staining of the Prss82/2 labyrinth (I). No expression was detected in the
trophoblast stem cell-containing chorionic epithelium (open arrowhead in H). Scale bars: A, C, D, F, G, and I, 100 mm; B, E, and H, 25 mm. (J) Enzymatic
activity of wildtype (red), V170D (blue), S238A (grey), and zymogen (black) forms of prostasin. Prostasin variants were incubated with 50 mM pERTKR-
AMC fluorogenic peptide at 37uC. V170D prostasin exhibited about 6% of the amidolytic activity of wildtype prostasin. No activity of catalytically
inactive prostasin or prostasin zymogen was detected. (K) Western blot detection of SDS-stable complexes between prostasin and protein nexin-1
(PN-1). Wildtype zymogen (lanes 1 and 2), activated wildtype (lanes 3 and 4), V170D (frizzy) zymogen (lanes 5 and 6), activated V170D (lanes 7 and 8),
S238A zymogen (lanes 9 and 10), and activated S238A (lanes 11 and 12) prostasin variants were incubated with (lanes 2, 4, 6, 8, 10, and 12) or without
(lanes 1, 3, 5, 7, 9, and 11) 250 ng of recombinant human PN-1. Wildtype, but not V170D or S238A variants of prostasin formed SDS-stable complexes
with PN-1. Positions of pro-prostasin, activated prostasin (migrating slightly faster than the zymogen due to removal of the 12 aa propeptide that is
not detected after 4–12% SDS/PAGE with anti-prostasin antibody), and prostasin/PN-1 complexes are indicated. Positions of molecular weight
markers (kDa) are shown on left.
doi:10.1371/journal.pgen.1002937.g002
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a strong cross reactivity of available anti-matriptase antibodies
with unrelated antigens. Similarly, direct detection of active
prostasin by western blot failed due to the small difference in the
electrophoretic mobility of the zymogen and the active form of the
enzyme (data not shown). In order to circumvent these problems,
we instead determined the amount of active matriptase and
prostasin that formed inhibitor complexes with endogenous HAI-1
in embryonic tissues from wildtype, matriptase-, and prostasin-
deficient embryos. Immunoprecipitation of protein extracts using
anti-mouse HAI-1 antibodies followed by western blot with
prostasin antibodies detected the presence of the 38 kDa band
in the placentas of wildtype mice (Figure 5C, lanes 2 and 4) and
matriptase-deficient mice (Figure 5C, lane 3). This band was not
detected in placental extracts from prostasin-deficient embryos
(Figure 5C, lane 1) or when anti-HAI-1 antibodies were omitted
from the assay (Figure 5D, compare lanes 1 and 2), indicating that
it represents the active form of prostasin released from an
inhibitory complex with HAI-1. In support of this, when prostasin
from either matriptase-deficient or littermate wildtype control
placental tissues was released from the immunoprecipitated HAI-
1-prostasin complexes by brief exposure to low pH, it was able to
form SDS-stable complex with PN-1, which requires the catalytic
activity of prostasin (Figure 5C, compare lane 3 with 5 and lane 4
with 6). Quantification of the amount of active prostasin in
Figure 3. Reduced prostasin activity restores placental development and embryonic survival of HAI-1–deficient mice. (A) Distribution
of genotypes of born offspring of intercrossed Spint1+/2;Prss8fr/2mice. No Spint12/2mice expressing one or two wildtype prostasin alleles (Prss8+/+ or
Prss8+/fr, blue bars) were identified, while Spint12/2 embryos carrying two mutant prostasin alleles (Prss8fr/fr, green bars) were found in near-expected
frequency. (B–G) Representative low (B–D) and high (E–G) magnification images showing the histological appearance of H&E-stained placental tissues
of (Spint1+;Prss8+) (B and E), (Spint12/2;Prss8+) (C and F), and (Spint12/2;Prss8fr/fr) (D and G) embryos at E11.5. The thickness of the placental labyrinth
(two-sided arrows between the dotted lines in B–D), as well as the number of fetal vessels (E–G, arrows) and lacunae filled with maternal blood (E–G,
arrowheads) within the labyrinth is markedly reduced in prostasin-sufficient (C and F), but not in prostasin-deficient (D and G) Spint12/2 embryos,
when compared to the controls (B and E). (H, I) Quantification of the maximum thickness of the labyrinth layer (H) and the number of fetal vessels in
the placental labyrinth (I) of Spint1+;Prss8+, Spint1+;Prss8fr/fr, Spint12/2;Psrr8+, and Spint12/2;Psrr8fr/fr embryos at E11.5. The thickness of the labyrinth
and fetal vessel density were strongly diminished in HAI-1-deficient mice but completely restored in HAI-1-deficient mice with low prostasin activity.
(J) Outward appearance of one-year-old Spint12/2;Prss8fr/fr and littermate Spint1+;Prss8+ mice. ***, p,0.0001, Student’s t-Test, two tailed. Scale bars:
B–D, 100 mm; E–G, 25 mm.
doi:10.1371/journal.pgen.1002937.g003
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Figure 4. Reduced prostasin activity restores placental differentiation, embryonic survival, and neural tube closure in HAI-2–
deficient mice. (A) Distribution of Spint2 genotypes in prostasin-sufficient (Prss8+/+ or Prss8+/fr) E9.5–11.5 offspring from interbred Spint2+/2;Prss8fr/+
mice. No Spint22/2 embryos were observed (P,0.025, Chi-square test). (B) Distribution of Spint2 genotypes in prostasin-sufficient (Prss8+/+ or Prss8+/fr,
blue bars) and prostasin-deficient (Prss8fr/fr, green bars) mouse embryos from interbred Spint2+/2;Prss8fr/+ mice at E13.5–15.5. No prostasin-expressing
Spint22/2 embryos were observed (P,0.001, Chi-square test), while survival of prostasin-deficient Spint22/2 embryos was restored. (C) Distribution of
Spint2 genotypes in newborn prostasin-sufficient, matriptase wildtype (Prss8+/+ or Prss8+/fr;St14+/+, blue bars), prostasin-deficient, matriptase wildtype
(Prss8fr/fr;St14+/+, green bars), and prostasin-deficient, matriptase haploinsufficient (Prss8fr/fr;St14+/2, red bars) offspring from Spint2+/2;Prss8fr/2
6Spint2+/2;Prss8fr/+;St14+/2 breeding pairs. Reduced prostasin activity restored embryonic survival of Spint22/2 mice partially in matriptase wildtype
and completely in matriptase haploinsufficient mice. (D–G) Macroscopic (D and E) and histological (H&E staining) (F and G) appearance of the HAI-2-
deficient, matriptase- and prostasin-sufficient (Spint22/2;Prss8+/+ or Prss8+/fr, St14+/2, D and F) or HAI-2- and prostasin-deficient, matriptase-sufficient
(Spint22/2;Prss8fr/fr, St14+/+ or St14+/2) (E and G) embryos at E9.5. HAI-2 deficiency prevents convergence of neural folds in the cranial region of neural
tube (D and F, arrows) leading to exencephaly. Convergence and fusion of neural folds are restored in HAI-2-deficient mice with low prostasin activity
(E and G, arrows). Presence of medial (F, open arrowhead) and absence of dorsolateral (F, arrowheads) hinge points. (H) Frequency of exencephaly in
E9.5–18.5 Spint22/2 embryos with different levels of prostasin activity (Prss8+/+, Prss8fr/+ or Psrr8fr/fr) and matriptase (St14+/+, St14+/2 or St142/2). The
frequency of neural tube defects is inversely correlated with the combined number of wildtype Prss8 and St14 alleles. A total of 524 embryos were
analyzed. (I–L) Histological appearance (H&E staining) (I and J), thickness of placental labyrinth (K), and number of fetal vessels within the labyrinth (L)
in the placentas of HAI-2 and prostasin-sufficient (Spint2+;Prss8+) and HAI-2 and prostasin double-deficient (Spint22/2;Prss8fr/fr) embryos at E12.5.
Reduced prostasin activity restores differentiation of placental labyrinth in Spint22/2 mice to levels not significantly (N.S.) different from wildtype
littermate controls. Arrows in I and J show examples of fetal vessels. Scale bars: F, 50 mm G, I, and J, 100 mm.
doi:10.1371/journal.pgen.1002937.g004
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Figure 5. Prostasin is required for the activation of matriptase during placental differentiation. (A and B) Expression of prostasin (A) and
matriptase (B) in placental tissues of wildtype mice at E11.5. Both proteins were expressed in the chorionic (arrows) and labyrinthine (arrowheads)
trophoblasts. (C) Western blot detection of active prostasin in the fetal part of the placenta of wildtype (Prss8+/+ and St14+/+, lanes 2, 4, and 6),
prostasin-deficient (St14+/+;Prss82/2) (lane 1), and matriptase-deficient (St142/2;Prss8+/+) (lanes 3 and 5) embryos at E11.5 after immunoprecipitation
with anti-mouse HAI-1 antibodies. Immunoprecipitated proteins in lanes 5 and 6 were acid-exposed to dissociate prostasin-HAI-1 complexes, and
then incubated with PN-1 prior to western blot analysis. Positions of bands corresponding to active prostasin, prostasin/PN-1 complex, as well as non-
specific signals of IgG heavy and light chains are indicated on the right. Positions of molecular weight markers (kDa) are shown on the left. (D)
Omission of anti-HAI-1 antibody resulted in loss of detectable prostasin (compare lanes 1 and 2), indicating that the detected prostasin formed
complexes with HAI-1. (E) Quantification of the relative amount of active prostasin in wildtype and matriptase placentae by densitometric scanning of
prostasin western blots of HAI-1 immunoprecipitated material from (Prss82/2;St14+/+, N = 3, Prss8+/+;St142/2, N = 3, and Prss8+/+;St14+/+, N = 6). Data
are shown as mean 6 standard deviation (N.S., not significant). (F and G) Western blot detection of active matriptase in the fetal part of the placenta
at E11.5 (F) after anti-HAI-1 immunoprecipitation, and in the epidermis of newborn skin (G) of wildtype (Prss8+/+ and St14+/+) (F, lanes 1, and 3, and G,
lane 2), prostasin-deficient (St14+/+;Prss82/2) (F, lane 4 and G, lane 1), and matriptase-deficient (St142/2;Prss8+/+) (F, lane 2, and G, lane 3) embryos. A
30 kDa band representing the active serine protease domain of matriptase (Mat SPD) was present in extracts from wildtype (lanes 1 and 3 in F), but
not in matriptase- (lane 2 in F) or prostasin-deficient (lane 4 in F) placenta. Zymogen (Mat FL) and active (Mat SPD) forms of matriptase were detected
in extracts from both wildtype and prostasin-deficient, but not matriptase-deficient epidermis. (H–H0) Immunohistochemical staining of matriptase in
control Prss8+ (H) and prostasin-deficient Prss82/2 (H9) placenta at E11.5. Specificity of staining of chorionic and labyrinthine trophoblasts (examples
with arrows) is shown by the absence of staining of corresponding cells in St142/2 placenta (H0). Insets in H and H9 are parallel sections stained with
prostasin antibodies. Open arrowheads in H–H0 show examples of non-specific staining. Scale bars: A, B, H, H9, and H0, 50 mm.
doi:10.1371/journal.pgen.1002937.g005
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wildtype and prostasin-deficient placentae by densitometric scans
of western blots showed that the loss of matriptase did not affect
the amount of active prostasin (Figure 5E). Taken together, these
data suggest that the developing placenta does not require
matriptase for the activation of prostasin.
Detection of matriptase by western blot after immunoprecipi-
tation with anti-HAI-1 antibodies revealed the presence of a
30 kDa band corresponding to the activated matriptase serine
protease domain in wildtype placental tissues, but not matriptase-
deficient placental tissues (Figure 5F, compare lanes 1 and 2).
Surprisingly, however, the active form of matriptase was also
absent in the extracts from prostasin-deficient placentae (Figure 5F,
compare lanes 3 and 4). The absence of matriptase was observed
in four independent experiments using placentae from a total of
seven prostasin-deficient mice and their prostasin-sufficient litter-
mate controls (Figure S1B and data not shown). As expected,
analysis of skin extracts from prostasin-deficient newborn mice and
wildtype littermate controls using the same western blot conditions
clearly showed the presence of the active form of matriptase in
both the control and prostasin-deficient mice (Figure 5G, compare
lanes 1 and 2 with lane 3), demonstrating that differences in the
functional relationship between the two proteases exist in different
tissues. Immunohistochemistry of placentae from littermate
control and prostasin-deficient embryos showed no obvious
difference in levels or pattern of matriptase expression (compare
Figure 5H and 5H9).
To further substantiate the above findings, we next determined
if prostasin could serve as an activator of matriptase in a
reconstituted cell-based assay. For this purpose, we transiently
transfected HEK-293 cells with expression vectors encoding HAI-
1 (to allow for efficient matriptase expression) and wildtype or
catalytically inactive matriptase. The transfected cells were then
exposed to soluble recombinant prostasin or vehicle, and
matriptase activation was analyzed six hours later by western blot
of cell lysates (Figure 6A) or conditioned medium (Figure 6B).
Interestingly, soluble prostasin efficiently activated matriptase, as
evidenced by the large increase in the amount of the liberated
matriptase serine protease domain (Mat SPD, Figure 6A and 6B,
compare lanes 1 and 2) after reducing SDS/PAGE, and a
corresponding diminution of the amount of matriptase zymogen
(Mat SEA, Figure 6A and 6B, compare lanes 1 and 2). Activation
site cleavage of matriptase by prostasin did not require matriptase
catalytic activity, as shown by the increased amount of the isolated
matriptase serine protease domain in prostasin-treated cells
expressing a catalytically inactive matriptase (Figure 6A and 6B,
compare lanes 3 and 4). Similar results were obtained when
matriptase-transfected HEK-293 cells were transfected with a
prostasin expression vector, rather than being treated with soluble
prostasin (data not shown). To investigate if the prostasin-activated
matriptase displayed functional activity, the HEK-293 cells
described above were also transfected with a PAR-2 expression
vector and a serum response element (SRE)-luciferase reporter
plasmid to measure PAR-2 activity (Figure 6C). Exposure of
serum-starved cells to soluble prostasin resulted in a large increase
in luciferase activity in cells transfected with wildtype matriptase
(Figure 6C, left panels), but not in cells transfected with
catalytically inactive matriptase (Figure 6C, second panels from
left), with HAI-1 alone (Figure 6C, second panels from right) or
with empty vector (Figure 6C, right panels). Taken together, the
data indicate that prostasin can proteolytically activate matriptase
and is critical for the generation of active matriptase during
placental development. Detection of active matriptase and
prostasin in the embryo by western blot or by anti-HAI-1
immunoprecipitation failed to detect either of the proteases, likely
due to the restricted expression of both proteins (data not shown).
Developmental defects in HAI-2–deficient embryos are
not caused by aberrant activity of the epithelial sodium
channel
Both matriptase and prostasin have been reported to activate
the epithelial sodium channel (ENaC) in cell-based assays, and
prostasin is a critical regulator of ENaC activity during alveolar
fluid clearance in mouse lungs and likely regulates ENaC activity
in many other adult organs [51,52]. Immunohistological analysis
of embryonic tissues at E11.5 revealed strong expression of ENaC
in the developing labyrinth layer of the placenta (Figure 6D). No
ENaC expression was detected in the embryo proper (data not
shown). To investigate a possible involvement of ENaC in the
etiology of prostasin-matriptase-induced developmental defects in
HAI-2-deficient mice, pregnant females from Spint2+/2 mice bred
to Spint2+/2;St14+/2 mice were treated daily between E5.5–8.5
with the pharmacological inhibitor of ENaC activity, amiloride,
which is known to cross the feto-maternal barrier [53]. Genotyp-
ing of embryos extracted at E9.5 from these crosses did not
identify any Spint22/2;St14+/+ embryos (Figure S1C), indicating
that the inhibition of ENaC activity is not sufficient to prevent
early embryonic lethality resulting from the loss of HAI-2.
Furthermore, all of the seven Spint22/2;St14+/2 embryos identi-
fied in this experiment exhibited exencephaly, suggesting that
ENaC activity is not critically involved in the etiology of neural
tube defects in HAI-2-deficient mice (Figure 6E). Similarly, genetic
inactivation of the a subunit of ENaC (encoded by Scnn1a), which
is necessary for channel activity in vivo [54,55], failed to rescue
embryonic development of HAI-2-deficient animals, as evidenced
by a complete absence of any surviving Spint22/2;Scnn1a2/2
double-deficient embryos at E9.5 from Spint2+/2;Scnn1a+/2 mice
bred to Spint2+/2;Scnn1a+/2 mice (Figure 6F) and the failure of
Spint22/2;Scnn1a2/2 double-deficient mice to appear in the
newborn offspring from Spint2+/2;Scnn1a+/2 mice bred to
Spint2+/2;Scnn1a+/2;St14+/2 mice (Figure 6G). Taken together,
these data do not support the critical involvement of aberrant
ENaC activity in the developmental defects resulting from lack of
HAI-2 regulation of the prostasin-matriptase proteolytic pathway.
Excess PAR-2 signaling does not cause developmental
defects in HAI-2–deficient mice
Matriptase and prostasin are co-expressed with PAR-2 in
surface ectoderm during neural tube closure ([43,45], this study),
and matriptase displays extraordinarily favorable activation
kinetics towards PAR-2 in cell-based assays [43,45]. Furthermore,
activation of PAR-2 (encoded by the F2rl1 gene) was recently
shown to contribute to neural tube closure (see below). These data
suggested that some, or all, of the prostasin- and matriptase-
dependent defects in HAI-2-deficient mice could be caused by
excess PAR-2 signaling. To test this hypothesis, we interbred
Spint2+/2;F2rl1+/2 mice and genotyped the ensuing embryos at
E9.5. This analysis failed to identify any Spint22/2;F2rl12/2
embryos (Figure 7A). Thus, the loss of PAR-2 activity is not
sufficient to overcome matriptase- and prostasin-dependent early
embryonic lethality in HAI-2-deficient mice. When the early
embryonic survival was improved by matriptase haploinsufficiency
(see above), analysis of neural tubes at E9.5 revealed exencephaly
in 100% of Spint22/2;F2rl12/2 St14+/2 embryos, identical to the
frequency of defects observed in littermate HAI-2-deficient
embryos expressing PAR-2 (Spint22/2;F2rl1+/+ or F2rl1+/2;
St14+/2) (Figure 7B). Thus, excess PAR-2 activation does not
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Figure 6. Prostasin activates matriptase on the surface of HEK293 cells. (A and B) Western blot detection of matriptase in cell lysates (A) and
in the conditioned medium (B) from HEK293 cells transiently transfected with wildtype recombinant human matriptase and HAI-1 expression vectors
(lanes 1 and 2), catalytically inactive (S805A) matriptase and HAI-1 (lanes 3 and 4), HAI-1 alone (lanes 5 and 6), and cells transfected with a control
empty vector (lanes 7 and 8) that were incubated with (lanes 2, 4, 6, and 8) or without (lanes 1, 3, 5, and 7) 100 nM soluble recombinant human
prostasin. Addition of prostasin promoted conversion of the matriptase zymogen to its activated two-chain form. Positions of bands corresponding
to full length matriptase (Mat FL), matriptase pro-enzyme processed by autocatalytic cleavage within the SEA domain (Mat SEA), and activated
matriptase serine protease domain (Mat SPD) are indicated on the right. Positions of molecular weight markers (kDa) are shown on left. (C)
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appear to be critically involved in the etiology of neural tube
defects in HAI-2-deficient mice.
Loss of matriptase does not cause neural tube defects in
PAR-1–deficient embryos
Rac1 activation in surface ectoderm through Gi, initiated by
either PAR-1 or PAR-2 activation was recently shown to be
required for neural tube closure. Thus, mice with combined, but
not single, deficiency in PAR-1 and PAR-2 display exencephaly
with high frequency [45]. As matriptase and prostasin are co-
expressed with PAR-2 in surface ectoderm during neural tube
closure ([43,45], this study), we next investigated if the prostasin-
matriptase cascade identified in the current study contributes to
physiological PAR-2 activation during neural tube closure. To test
this, we generated mice with combined deficiency in PAR-1
(encoded by the F2r gene) and matriptase (F2r2/2;St142/2). If
matriptase was essential for the activation of PAR-2 during neural
tube closure, these mice should phenocopy mice with a combined
PAR-1 and PAR-2 deficiency, including embryonic lethality and
high susceptibility to cranial neural tube defects [45]. However,
analysis of the midgestation embryos from intercrossed
F2r+/2;St14+/2 mice yielded the expected distribution of all
genotypes (Figure 7C). Furthermore, none of 20 observed F2r2/
2;St142/2 mice displayed cranial neural tube defects, although the
PAR-1 deficiency alone or in combination with matriptase
deficiency occasionally led to defects in the closure of the posterior
neural tube, resulting in spina bifida and curly tail (Figure 7D).
HAI-2 and PAR-1/PAR-2 regulate different stages of
neural tube development
The lack of functional interaction between prostasin-matriptase
and PAR-1/PAR-2 regulated signaling pathways evidenced from
the above experiments suggested that the two pathways are either
involved in two essential, non-redundant mechanisms regulating
the same steps of neural tube closure, or that they may regulate
different stages of the process. To distinguish between the two
possibilities, we performed a detailed morphologic comparison of
the neural tube defects caused by loss of HAI-2 and by the
combined loss of PAR-1 and PAR-2. Macroscopic analysis showed
significant differences in the types of neural tube defects in the two
mutant mouse strains. In PAR-1 and PAR-2 double-deficient
mice, the defects were almost exclusively restricted to the
hindbrain region of the cranial neural tube (Figure 7E and
Table 2). In addition, PAR-1 and PAR-2 double-deficient embryos
did not exhibit any obvious abnormalities during the early stages
of neural tube closure, as all of the embryos analyzed before E10.5
showed normal elevation and conversion of the opposing neural
folds, as well as the completion of the neural fold fusion at initial
closure points 1 and 2 at hindbrain/cervix and forebrain/
midbrain boundaries, respectively (compare Figure 7F with 7G,
and 7F9 with 7G9). As a result, the neural tube defects in these
mice were generally only obvious after E10.5 (compare Figure 7H
with 7I and 7J), and were generally restricted to the hindbrain
region of the neural tube, with less than five percent exhibiting
exencephaly that extended to the midbrain region (Figure 7I and
Table 2). In contrast, HAI-2 deficiency was generally associated
with a failure of cranial neural tube closure that was obvious at
E9.5 or earlier, and was due to the inability of neural folds to
elevate properly, and to come into juxtaposition necessary for the
fusion (compare Figure 7F with 7K, and 7F9 with 7K9). The fusion
at closure point 1 of HAI-2-deficient mice was completed in all
embryos analyzed at E9.5 or later, and no case of craniorachis-
chisis was observed (Table 2). However, 10 percent of Spint22/2
embryos failed to initiate fusion at closure point 2, resulting in
exencephaly that extended from forebrain region to the hindbrain-
cervical boundary (Figure 7K and 7K9). In addition, even in the
embryos that successfully initiated the fusion at closure point 2, the
exencephaly was more extensive than the one observed in PAR-1
and PAR-2 double-deficient embryos, typically spanning the entire
midbrain and hindbrain regions (compare Figure 7L and 7I).
Finally, histological analysis of affected embryos at E9.5 showed
that dorsolateral hinge points (DLHPs) critical for the final stages
of the neural tube closure were absent in 97 percent of Spint22/2
embryos (Figure 4D and 4F, Figure 7K and 7K9, and Table 2),
while F2r2/2;F2rl12/2 embryos generally exhibited DLHP
formation indistinguishable from wildtype littermate controls
(Figure 7G, 7G9, and 7M, compare to Figure 4E, 4G, Figure 7F
and 7F9). Thus, substantial differences are observed in the
location, frequency, extent, and onset of the neural tube defects
of HAI-2-deficient mice and PAR-1 and PAR-2 double-deficient
mice, further indicating the independent roles of, respectively,
repression and activation of the two protease-regulated pathways
in distinct stages of neural tube formation.
Discussion
In this study, we exploited the uniform matriptase-dependent
embryonic lethality of mice deficient in hepatocyte growth factor
activator inhibitors as a means to genetically identify novel
molecules and pathways regulating and being regulated by
matriptase in the developing embryo by epistasis analysis. This
analysis resulted in a number of unexpected findings. First, we
found that prostasin is an essential component of the matriptase-
dependent molecular machinery that causes early embryonic
lethality, derails placental labyrinth formation, and causes defects
in neural tube closure in these mice. This shows that both proteins
are expressed, are active, functionally interact, and must be
regulated by hepatocyte growth factor activator inhibitors already
during early development. Surprisingly, however, rather than
being a downstream effector of matriptase function, as previously
established for both mouse and human epidermis ([23,24,25,26],
this study), prostasin acts upstream of matriptase during embryo-
genesis and is essential for activation of the matriptase zymogen.
Quantification of the activation of PAR-2 in HEK293 cells expressing recombinant human PAR-2 in combination with wildtype (WT) or inactive (S805A)
variants of matriptase and HAI-1, HAI-1 alone, or transfected with an empty vector, incubated without (blue bars) or with (red bars) 100 nM soluble
recombinant human prostasin. Prostasin induced matriptase activity-dependent activation of PAR-2. (D) Immunohistochemical analysis of the
expression of the gamma subunit of the epithelial sodium channel (ENaC) in placenta of control mice at E11.5. The expression was detected in the
populations of chorionic (arrow) and labyrinthine (arrowhead) trophoblasts. Scale bar: 50 mm. (E) Frequency of exencephaly in amiloride-treated
wildtype (Spint2+/+, N = 56), untreated HAI-2-deficient (Spint22/2, N = 12) and amiloride-treated HAI-2-deficient (Spint22/2, N = 7) embryos at E9.5.
Amiloride treatment failed to rescue neural tube defects in Spint22/2; St14+/2 embryos. (F) Distribution of Spint2 genotypes in ENaC-expressing
(Scnn1a+/+ or Scnn1a+/2, blue bars) and ENaC-deficient (Scnn1a2/2, green bars) offspring from Spint2+/2;Scnn1a+/26Spint2+/2;Scnn1a+/2 breeding
pairs at E9.5. Loss of ENaC expression did not rescue early embryonic lethality in Spint22/2 mice. (G) Distribution of Spint2 genotypes in matriptase-
haploinsufficient ENaC-expressing (St14+/2;Scnn1a+/+ or Scnn1a+/2, blue bars) and ENaC-deficient (St14+/2; Scnn1a2/2, green bars) offspring from
Spint2+/2;Scnn1a+/2, St14+/26Spint2+/2;Scnn1a+/2;St14+/+ breeding pairs at birth. Loss of ENaC expression did not rescue overall embryonic survival in
Spint22/2; St14+/2 mice.
doi:10.1371/journal.pgen.1002937.g006
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Figure 7. Neural tube defects and embryonic lethality in HAI-2–deficient mice are not dependent on PAR-2, and combined PAR-1
and matriptase deficiency does not phenocopy combined PAR-1 and PAR-2 deficiency. (A) Distribution of Spint2 genotypes at E9.5 in
PAR-2-expressing (F2rl1+/+ or F2rl1+/2, blue bars) and PAR-2-deficient (F2rl12/2, green bars) offspring from interbred Spint2+/2,F2rl1+/2 mice. No
Spint22/2 embryos were detected irrespective of PAR-2 expression. (B) Frequency of exencephaly observed in HAI-2 and PAR-2-sufficient
(Spint2+;F2rl1+ N=366), PAR-2-deficient (Spint2+;F2rl12/2, N = 164), HAI-2-deficient (Spint22/2,F2rl1+, N = 18), and PAR-2 and HAI-2 double-
(Spint22/2;F2rl12/2, N = 12) deficient embryos extracted at E9.5–E11.5. Loss of PAR-2 activity fails to correct neural tube defects in HAI-2-deficient
embryos. (C) Distribution of St14 alleles at E11.5–15.5 in PAR-1-expressing (F2r+/+ or F2r+/2, blue bars) and PAR-1-deficient (F2r2/2, green bars)
embryos from interbred St14+/2;F2r+/2 mice. Loss of PAR-1 activity does not affect embryonic survival of matriptase-deficient mice. (D) Frequency of
exencephaly (Ex), spina bifida (SB), and curly tail (CT) in E9.5–18.5 embryos with different levels of expression of PAR-1 (F2r+ or F2r2/2) and matriptase
(St14+or St142/2). A total of 326 embryos were analyzed. Loss of matriptase does not significantly increase the incidence of neural tube defects in
PAR-1-deficient embryos. (E) Comparison of the severity of exencephaly in HAI-2-deficient (Spint22/2, N = 29) and PAR-1 and PAR-2 double-deficient
(F2r2/2;F2rl12/2, N = 39) embryos. 95% of affected F2r2/2;F2rl12/2 embryos exhibited exencephaly that was confined to hindbrain region of the
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This finding is perplexing, as matriptase is well-established to be
able to auto-activate, as most clearly evidenced by the inability of
recombinant matriptase protein with the catalytic triad serine
mutated to alanine (S805A matriptase) to undergo activation site
cleavage [56]. Furthermore, prostasin shows no catalytic activity
towards peptide sequences derived from the prostasin pro-peptide
[57] and no reports of prostasin auto-activation have appeared to
date. Substantiating this finding, however, we found that prostasin
efficiently activated the matriptase zymogen in a reconstituted cell-
based assay. These findings are aligned with a recent study
showing that PAR-2 activation in some cultured cells, caused by
exposure of cultured cells to exogenously added activated
prostasin, was blunted by a neutralizing antibody directed against
matriptase [45], providing further evidence that complex and
context-specific relationships between the two membrane-an-
chored serine proteases may exist in vivo. Another important
finding relating to the developmental prostasin-matriptase cascade
identified in this study emanated from our biochemical analysis of
placental tissues, which revealed that activated forms of both
matriptase and prostasin were present in a complex with HAI-1 in
placental tissues. This indicates that the regulation of the prostasin-
matriptase cascade by HAI-1 (and likely HAI-2) may occur by
controlling both prostasin and matriptase proteolytic activity.
Furthermore, as both HAI-1 and HAI-2 are very promiscuous and
display potent inhibitory activity towards a number of trypsin-like
serine proteases in vitro [58,59,60,61,62,63,64], it is throughout
plausible that they may also regulate the activity of as yet
unidentified proteases that act upstream of, downstream of or
between prostasin and matriptase. Such profound complexities in
zymogen activation relationships between trypsin-like serine
proteases and for the promiscuity of their cognate inhibitors have
long been recognized in the coagulation, fibrinolytic, complement,
and digestive systems. The current findings, thus, serve to
underscore that our knowledge of the molecular workings of
membrane-anchored serine proteases is still fragmentary, due to
their quite recent emergence as a protease subfamily.
The outcome of our epistasis analysis querying the contribution
of proHGF, PAR-2, and ENaC to the prostasin and matriptase-
dependent embryonic demise of HAI-1- and HAI-2-deficient mice
also was unanticipated. Each of the three proteins has been
genetically validated as a substrate for either matriptase or
prostasin in developmental or post-developmental processes, has
established functions in embryonic development, and is develop-
mentally co-expressed with both proteases. Nevertheless, their
genetic elimination failed to prevent or alleviate any of the
abnormalities caused by the loss of HAI-1 or HAI-2. Importantly,
our analysis does not exclude that cleavage of either of the three
proteins must be suppressed by HAI-1 or HAI-2 at later stages of
development that cannot be analyzed by the current experimental
approach. Also, the possibility that the lethality of HAI-1- or HAI-
2-deficient embryos is caused by the simultaneous cleavage of
more than one of these substrates cannot be formally excluded. It
was particularly surprising that the neural tube defects associated
with HAI-2-deficiency were unrelated to either excessive or
reduced (through desensitization) PAR-2 activity, despite the
unequivocal contribution of PAR-2 signaling to neural tube
closure, and the wealth of strong circumstantial evidence that
prostasin and matriptase contribute to PAR-2 activation in this
process [45,65]. Equally surprising in this regard, the combined
loss of PAR-1 and matriptase failed to cause the neural tube
closure defects observed in PAR-1 and PAR-2 double-deficient
embryos, showing that matriptase is not essential for initiation of
physiological PAR-2 signaling during neural tube formation.
Previous analysis has identified five other membrane-anchored
serine proteases and fourteen secreted trypsin-like serine proteases
that are expressed during neural tube formation, some of which
can activate PAR-2 in cell-based assays [43,45]. It is therefore
possible that the prostasin-matriptase cascade does contribute to
PAR-2 activation during neural tube closure, but sufficient
residual activation of PAR-2 by other developmentally co-
expressed serine proteases takes place in its absence to allow for
completion of this developmental process. Nevertheless, the careful
comparison of the morphology of neural tube defects in PAR-1
and PAR-2, and HAI-2-double deficient embryos performed here
revealed distinct differences in terms of their anatomical location
and the stage of developmental failure. Taken together, these data
suggest that promotion of neural tube closure by HAI-2
suppression of the prostasin-matriptase cascade and promotion
of neural tube closure by PAR-1/PAR-2 signaling may be
temporally and spatially distinct morphogenic processes.
In conclusion, this study identifies a prostasin-matriptase cell
surface protease cascade whose activity must be suppressed by
cranium (HB only, green bars), with the remaining 5% extending to the midbrain region (MB-HB, blue bars). In contrast, only 10% of exencephalies
observed in Spint22/2-deficient mice were confined to the hindbrain, with 59% extended to midbrain, and 31% to forebrain region (FB-HB, red bars).
(F–G9) Ventral (F and G) and dorsal (F9 and G9) view of non-affected control (F and F9) and affected PAR-1 and PAR-2 double-deficient (F2r2/2;F2rl12/
2) (G and G9) embryos at E9.5. The initial stages of neural tube closure all appear to be unaffected by the combined absence of PAR-1 and PAR-2. (H–
J) Appearance of control (H) and PAR-1 and PAR-2 double-deficient embryos with exencephaly (I and J) at E14.5. Exencephaly in 95% of the affected
PAR-1 and PAR-2 double-deficient embryos was restricted to hindbrain region (HB, two-sided arrow in I) and extended to midbrain (MB-HB, two-sided
arrow in J) in only 5% of the cases. (K and K9) Ventral (K) and dorsal (K9) view of the macroscopic appearance of HAI-2-deficient (Spint22/2) embryos at
E9.5. Divergence of neural folds (arrows) and defects in neural tube closure extending from forebrain region to cervix are obvious. Open arrowheads
show normal formation of medial hinge points. (L) Macroscopic appearance of a HAI-2-deficient embryo with exencephaly at E14.5. 90% of embryos
presented with exencephaly that included at least midbrain and hindbrain regions of the developing cranium. (M) Histological appearance (nuclear
fast red staining) of PAR-1 and PAR-2 double-deficient embryo with exencephaly at E9.5. Defined medial (arrow) and dorsolateral (arrowheads) hinge
points are clearly visible. Scale bar: 150 mm.
doi:10.1371/journal.pgen.1002937.g007
Table 2. Comparison of morphologic features of neural tube
defects observed in Spint22/2 and F2r2/2; F2rl12/2 mice.
Spint22/2 F2r2/2; F2rl12/2
Process
Formation of medial hinge point 100% (28/28) 100% (38/38)
Formation of dorsolateral hinge points 3% (1/31) 97% (28/29)
Completion of C1 fusion 100% (28/28) 100% (66/66)
Completion of C2 fusion 90% (27/30) 100% (66/66)
Extent of neural tube defect
Hindbrain only 10% (3/29) 95% (37/39)
Hindbrain and midbrain 59% (17/29) 5% (2/39)
Forebrain to cervix 31% (9/29) 0% (0/39)
Craniorachischisis 0% (0/29) 0% (0/39)
doi:10.1371/journal.pgen.1002937.t002
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HAI-1 and HAI-2 to enable early embryonic ectoderm formation,
placental morphogenesis, and neural tube closure.
Materials and Methods
Mouse strains
All experiments were performed in an Association for Assess-
ment and Accreditation of Laboratory Animal Care International-
accredited vivarium following Standard Operating Procedures. The
studies were approved by the NIDCR Institutional Animal Care
and Use Committee. All studies were littermate controlled.
Spint12/2, Spint22/2, St142/2, Hgfr2/2, F2r2/2, F2rl12/2,
Scnn1a2/2, and Prss8fr/fr mice have been described
[38,40,43,49,66,67,68]. Prostasin-deficient (Prss82/2) mice were
generated by standard blastocyst injection of C57BL/6J-derived
embryonic stem cells carrying a gene trap insertion in the Prss8 gene
(clone IST10122F12, Texas A&M Institute for Genomic Research,
College Station, TX).
Extraction of embryonic and perinatal tissues
Breeding females were checked for vaginal plugs in the morning
and the day on which the plug was found was defined as the first
day of pregnancy (E0.5). Pregnant females were euthanized in the
mid-day at designated time points by CO2 asphyxiation. Embryos
were extracted by Caesarian section and the individual embryos
and placentae were dissected and processed. Visceral yolk sacs of
individual embryos were washed twice in phosphate buffered
saline, subjected to genomic DNA extraction and genotyped by
PCR (see Table S1 for primer sequences). Newborn pups were
euthanized by CO2 inhalation at 0uC. For histological analysis, the
embryos and newborn pups were fixed for 18–20 hrs in 4%
paraformaldehyde (PFA) in PBS, processed into paraffin, sec-
tioned, and stained with hematoxylin and eosin (H&E), or used for
immunohistochemistry as described below. For histomorphomet-
ric analysis of placental labyrinth, the midline cross sections of
plancetal tissues were stained with H&E and the thickness of the
labyrinth was determined as the maximum perpendicular distance
of fetal vessel from the chorionic trophoblast layer.
Immunohistochemistry
Antigens from 5 mm paraffin sections were retrieved by
incubation for 10 min at 37uC with 10 mg/ml proteinase K
(Fermentas, Hanover, MD) for HAI-1 staining, or by incubation
for 20 min at 100uC in 0.01 M sodium citrate buffer, pH 6.0, for
all other antigens. The sections were blocked with 2% bovine
serum albumin in PBS, and incubated overnight at 4uC with
rabbit anti-human CD31 (1:100, Santa Cruz Biotechnology, Santa
Cruz, CA), goat anti-mouse HAI-1 (1:200, R&D Systems,
Minneapolis, MN), mouse anti-human prostasin (1:200, BD
Transduction Laboratories, San Jose, CA), sheep anti-human
matriptase (1:200, R&D Systems) or ENaCc subunit (1:100,
Sigma-Aldrich, St. Louis, MO) primary antibodies. Bound
antibodies were visualized using biotin-conjugated anti-mouse, -
rabbit, -sheep or -goat secondary antibodies (all 1:400, Vector
Laboratories, Burlingame, CA) and a Vectastain ABC kit (Vector
Laboratories) using 3,39-diaminobenzidine as the substrate (Sig-
ma-Aldrich). All microscopic images were acquired on an
Olympus BX40 microscope using an Olympus DP70 digital
camera system (Olympus, Melville, NY).
Protein extraction from mouse tissues
Placentae were extracted from embryos at E10.5 or E11.5. The
embryonic portion of each placenta was manually separated from
maternal decidua using a dissecting microscope. The tissues were
then homogenized in ice-cold 50 mM Tris/HCl, pH 8.0; 1% NP-
40; 500 mM NaCl buffer and incubated on ice for 10 minutes.
The lysates were centrifuged at 20,000 g for 10 min at 4uC to
remove the tissue debris and the supernatant was used for further
analysis as described below.
Detection of active matriptase and prostasin in mouse
embryonic tissues
Lysates from two placentae of the same genotype were
combined and pre-incubated with 100 ul GammaBind G
Sepharose beads (GE Healthcare Bio-Sciences, Uppsala, Sweden)
for 30 minutes at 4uC with gentle agitation. The samples were
spun at 5,000 g for 1 min to remove the beads, and the
supernatant was then incubated with 5 mg goat anti-mouse HAI-
1 antibody (R&D Systems) and 100 ul of GammaBind G
Sepharose beads for 3 hours at 4uC. The samples were spun at
5,000 g for 1 min, the supernatant was removed, and the beads
were washed 3 times with 1 ml ice-cold 50 mM Tris/HCl,
pH 8.0; 1% NP-40; 500 mM NaCl buffer. The beads were then
mixed with 30 ul of 16SDS loading buffer (Invitrogen, Carlsbad,
CA) with 0.25 M b-mercaptoethanol, incubated for 5 min at
99uC, and cooled on ice for 2 minutes. The samples were spun at
5,000 g for 1 min and the released proteins were resolved by SDS-
PAGE (4–12% polyacrylamide gel) and analyzed by western blot
using mouse anti-human prostasin (1:250, BD Transduction Labs)
or sheep anti-human matriptase (1:500, R&D Systems) primary
antibodies and goat anti-mouse (DakoCytomation) or donkey anti-
sheep (Sigma-Aldrich) secondary antibodies (both 1:1000) conju-
gated to alkaline phosphatase, and visualized using nitro-blue
tetrazolium and 5-bromo-4-chloro-39-indolyphosphate.
Amiloride injections
Five ug per g of body weight of amiloride (Sigma-Aldrich) in
10% DMSO in PBS was administered to pregnant females by
intraperitoneal injection every 24 hours starting on E5.5. Embryos
were extracted on E9.5 by Caesarian section and genotyped as
described, and scored for neural tube closure defects.
Generation of soluble recombinant wildtype, catalytically
inactive S238A, and V170D prostasin zymogens
The generation of pIRES2-EGFP-prostasin has been described
[26]. Substitution of the native prostasin activation site (APQAR)
by the enteropeptidase-dependent cleavage site (DDDDK), and
either the S238A or V170D point mutations were introduced
using the QuickChange Kit (Stratagene, La Jolla, CA) and the




CAT-39. Successful mutagenesis was verified by sequencing of
both strands of the resulting cDNA. Expression plasmids carrying
individual mutations were transiently transfected into HEK-293T
cells using Turbofect (Fermentas). The cells were grown for two
days and soluble recombinant prostasin was prepared by
treatment of cells with phosphatidylinositol-specific phospholipase
C (Sigma-Aldrich) as described previously [26].
Determination of enzymatic activity of recombinant
prostasin variants
Recombinant wildtype, V170D Frizzy or catalytically inactive
S238A prostasin zymogen variants were first incubated with 5.1 U
recombinant bovine enteropeptidase (Novagen, Cambridge, MA)
overnight at 37uC in enterokinase buffer (Novagen). Following
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enteropeptidase removal using the Enterokinase Removal Kit
(Sigma-Aldrich), the protein concentration was estimated by
western blot of serially diluted proteins using a reference with
known protein concentration. For substrate hydrolysis assays, the
activated prostasin variants (62.5 nM) were incubated with the
fluorogenic substrate pERTKR-AMC (50 mM final concentration)
(R&D systems) at 37uC in 50 mM NaCl, 50 mM Tris-HCl
pH 8.8, 0.01% Tween-20 buffer, and the fluorescence was
measured using a Wallac plate reader (Perkin Elmer, Waltham,
MA). Each measurement was performed in triplicate. For serpin
complex formation, prostasin variants were diluted in 50 mM
Tris-HCl, pH 9.0, 50 mM NaCl, 0.01% Tween 20 to a final
concentration of 150 nM, incubated with 250 ng recombinant
human protease nexin-1 (PN-1) (R&D Systems) for 1 h at 37uC,
and analyzed using 12% reducing SDS-PAGE and western
blotting, using a monoclonal anti-prostasin antibody (BD Trans-
duction Laboratories).
Matriptase activation and SRE–luciferase assay
HEK 293 cells were plated in 24-well plates and grown in
DMEM supplemented with 10% FBS for 24 h. Cells were co-
transfected with pSRE-firefly luciferase (50 ng), pRL-Renilla
luciferase (20 ng), pcDNA 3.1 Par2 (100 ng) (Missouri S&T
cDNA Resource Center) using Lipofectamine and Plus reagent
(Invitrogen), pcDNA 3.1 expression vectors containing wildtype
human matriptase or catalytically dead matriptase (S805A), full
length human HAI-1 [69] and empty pcDNA 3.1 vector to
equalize the total amount of transfected DNA. After 36 h the cells
were serum starved over night and then stimulated with 100 nM
recombinant human soluble prostasin (R&D) or vehicle for 6 h.
Cell were lysed and luciferase activity was determined using the
dual luciferase assay kit (Promega, Madison, WI) according to the
manufacturer’s instructions. Chemiluminiscence was measured
using Microtiter Plate Luminometer (Dynex Technologies,
Chantilly, VA) and the SRE activation was determined as the
ratio of firefly to Renilla luciferase counts. The assay was
performed two times in duplicates.
Supporting Information
Figure S1 (A) Western blot detection of protein nexin-1 (PN-1).
Wildtype zymogen (lanes 1 and 2), activated wildtype (lanes 3 and
4), V170D (frizzy) zymogen (lanes 5 and 6), activated V170D
(lanes 7 and 8), S238A zymogen (lanes 9 and 10), and activated
S238A (lanes 11 and 12) prostasin variants were incubated with
(lanes 2, 4, 6, 8, 10, and 12) or without (lanes 1, 3, 5, 7, 9, and 11)
250 ng of recombinant human PN-1. Position of PN-1, and
predicted position of prostasin/PN-1 complexes (not detected by
anti-PN-1 antibody presumably due to significant molecular
rearrangement of PN-1 in the complex with the protease) are
indicated. Positions of molecular weight markers (kDa) are shown
on left. (B) Western blot detection of active matriptase in the fetal
part of the E11.5 placentas of one matriptase-deficient
(St142/2;Prss8+/+) (lane 1), three wildtype (Prss8+/+ and St14+/+)
(lanes 2,3, and 4), and three prostasin-deficient (St14+/+;Prss82/2)
(lanes 5, 6, and 7) embryos after anti-HAI-1 immunoprecipitation.
A 30 kDa band representing the active serine protease domain of
matriptase (Mat SPD) was present in extracts from wildtype, but
not in matriptase- or prostasin-deficient placentas. (C) Distribution
of Spint2 genotypes at E9.5 in offspring from interbred Spint2+/2
breeding pairs treated with the ENaC inhibitor, amiloride, at
E5.5–8.5. No Spint22/2 embryos were observed.
(TIF)
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